NCT04146038View on ClinicalTrials.gov

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 26, 2020

Primary Completion Date

October 25, 2021

Study Completion Date

October 25, 2022

Conditions
Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyeloblasts 10 Percent or More of Bone Marrow Nucleated CellsMyelodysplastic SyndromeMyeloproliferative NeoplasmRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia
Interventions
DRUG

Azacitidine

Given IV

DRUG

Decitabine

Given IV

DRUG

Salsalate

Given PO

DRUG

Venetoclax

Given PO

Trial Locations (1)

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Rutgers, The State University of New Jersey

OTHER

NCT04146038 - Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | Biotech Hunter | Biotech Hunter